POWERED BY

Isomorphic Labs and MSD enter strategic research collaboration

PublishedNovember 20, 2026

Isomorphic Labs, an AI-focused drug discovery and development company, and MSD (known as Merck & Co., Inc. in the United States and Canada), have announced a research collaboration combining Isomorphic Labs’ artificial intelligence capabilities with MSD’s proprietary data resources and drug discovery expertise. The company is headquartered in London, with additional offices in Cambridge, Massachusetts, and Lausanne, Switzerland.

The companies will work together to identify potential small-molecule drug candidates targeting an oncology target of strategic importance.

Under the agreement, Isomorphic Labs will use its proprietary drug design engine, IsoDDE, to conduct computational predictions and develop molecular designs. The work will incorporate selected proprietary datasets provided by MSD for the collaboration.

MSD will be responsible for the preclinical and clinical development of any resulting candidates, as well as their manufacturing and commercialisation.

As part of the agreement, Isomorphic Labs will receive an upfront payment and may receive additional payments upon achieving specified research, development, regulatory and commercial milestones. The agreement also includes tiered royalties on net sales. In addition, Isomorphic Labs has the option to co-fund development activities in exchange for higher royalty payments.

“Through this collaboration with MSD, we will apply our world-leading drug design engine to unlock significant discovery progress,” said Sarah Skerratt, Chief Research Officer at Isomorphic Labs. She added that the partnership would use the generative and predictive capabilities of IsoDDE to address a challenging drug discovery programme and support the development of treatments for patients with unmet medical needs.

George Addona, Senior Vice President and Head of Discovery, Preclinical Development and Translational Medicine at MSD Research Laboratories, highlighted the importance of integrating laboratory research with computational approaches when applying AI and machine learning to molecular discovery.

By combining MSD’s internal data resources and drug discovery expertise with Isomorphic Labs’ computational modelling capabilities, the companies aim to identify new approaches to designing and developing drug candidates more efficiently.

The collaboration brings together artificial intelligence, proprietary datasets and pharmaceutical research expertise to support the development of potential new treatments targeting complex biological mechanisms.

Founded in 2021, Isomorphic Labs aims to transform drug discovery through artificial intelligence and advance biomedical research.

The company is led by CEO Sir Demis Hassabis and President Max Jaderberg. It has developed IsoDDE, a drug design engine built on foundational AI models and designed to support drug discovery across different therapeutic modalities.

The platform uses computational models to predict biological systems and support the design of new drug candidates. Isomorphic Labs continues to develop its AI models and computational capabilities to advance drug discovery.

Isomorphic Labs is developing a drug discovery portfolio through collaborations with pharmaceutical partners and its own internal research programmes.

Source